Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 234

1.

Determination of galectin-3 messenger ribonucleic Acid overexpression in papillary thyroid cancer by quantitative reverse transcription-polymerase chain reaction.

Bernet VJ, Anderson J, Vaishnav Y, Solomon B, Adair CF, Saji M, Burman KD, Burch HB, Ringel MD.

J Clin Endocrinol Metab. 2002 Oct;87(10):4792-6.

PMID:
12364475
2.

Galectin-3 messenger ribonucleic acid and protein are expressed in benign thyroid tumors.

Martins L, Matsuo SE, Ebina KN, Kulcsar MA, Friguglietti CU, Kimura ET.

J Clin Endocrinol Metab. 2002 Oct;87(10):4806-10.

PMID:
12364477
3.

Galectin-3: presurgical marker of thyroid follicular epithelial cell-derived carcinomas.

Saggiorato E, Aversa S, Deandreis D, Arecco F, Mussa A, Puligheddu B, Cappia S, Conticello S, Papotti M, Orlandi F.

J Endocrinol Invest. 2004 Apr;27(4):311-7.

PMID:
15233548
4.

Galectin-3 is a presurgical marker of human thyroid carcinoma.

Orlandi F, Saggiorato E, Pivano G, Puligheddu B, Termine A, Cappia S, De Giuli P, Angeli A.

Cancer Res. 1998 Jul 15;58(14):3015-20.

5.

Detection of high mobility group I HMGI(Y) protein in the diagnosis of thyroid tumors: HMGI(Y) expression represents a potential diagnostic indicator of carcinoma.

Chiappetta G, Tallini G, De Biasio MC, Manfioletti G, Martinez-Tello FJ, Pentimalli F, de Nigris F, Mastro A, Botti G, Fedele M, Berger N, Santoro M, Giancotti V, Fusco A.

Cancer Res. 1998 Sep 15;58(18):4193-8.

6.

Immunohistochemical localization of galectin-3 in malignant and benign human thyroid tissue.

Cvejic D, Savin S, Paunovic I, Tatic S, Havelka M, Sinadinovic J.

Anticancer Res. 1998 Jul-Aug;18(4A):2637-41.

PMID:
9703921
7.

Differential reactivity for galectin-3 in Hürthle cell adenomas and carcinomas.

Nascimento MC, Bisi H, Alves VA, Longatto-Filho A, Kanamura CT, Medeiros-Neto G.

Endocr Pathol. 2001 Fall;12(3):275-9.

PMID:
11740048
8.

Expression of galectin-3 in fine-needle aspirates as a diagnostic marker differentiating benign from malignant thyroid neoplasms.

Inohara H, Honjo Y, Yoshii T, Akahani S, Yoshida J, Hattori K, Okamoto S, Sawada T, Raz A, Kubo T.

Cancer. 1999 Jun 1;85(11):2475-84.

PMID:
10357421
9.

Immunohistochemical expression of HBME-1 and galectin-3 in the differential diagnosis of follicular-derived thyroid nodules.

Abd-El Raouf SM, Ibrahim TR.

Pathol Res Pract. 2014 Dec;210(12):971-8. doi: 10.1016/j.prp.2014.06.010. Epub 2014 Jun 27.

PMID:
25041837
10.

Decreased relative expression level of trefoil factor 3 mRNA to galectin-3 mRNA distinguishes thyroid follicular carcinoma from adenoma.

Takano T, Miyauchi A, Yoshida H, Kuma K, Amino N.

Cancer Lett. 2005 Feb 28;219(1):91-6.

PMID:
15694668
11.

Molecular classification of thyroid nodules by cytology.

Pagedar NA, Chen DH, Wasman JK, Savvides P, Schluchter MD, Wilhelm SM, Lavertu P.

Laryngoscope. 2008 Apr;118(4):692-6.

PMID:
18094649
12.

Galectin-3 does not reliably distinguish benign from malignant thyroid neoplasms.

Mehrotra P, Okpokam A, Bouhaidar R, Johnson SJ, Wilson JA, Davies BR, Lennard TW.

Histopathology. 2004 Nov;45(5):493-500.

PMID:
15500653
13.

[Expression of galectin-3 in thyroid gland and follicular cell tumors of the thyroid. A critical study of its possible role in preoperative differential diagnosis].

Niedobitek C, Niedobitek F, Lindenberg G, Bachler B, Neudeck H, Zuschneid W, Hopfenmüller W.

Pathologe. 2001 May;22(3):205-13. German.

PMID:
11402851
14.

Galectin-3 and oncofetal-fibronectin expression in thyroid neoplasia as assessed by reverse transcription-polymerase chain reaction and immunochemistry in cytologic and pathologic specimens.

Giannini R, Faviana P, Cavinato T, Elisei R, Pacini F, Berti P, Fontanini G, Ugolini C, Camacci T, De Ieso K, Miccoli P, Pinchera A, Basolo F.

Thyroid. 2003 Aug;13(8):765-70.

PMID:
14558920
15.

[Expression of cytokeratin19, galectin-3 and HBME-1 in thyroid lesions and their differential diagnoses].

Teng XD, Wang LJ, Yao HT, Li J, Ding W, Yan LP.

Zhonghua Bing Li Xue Za Zhi. 2004 Jun;33(3):212-6. Chinese.

PMID:
15256110
16.

Galectin-3 and laminin expression in neoplastic and non-neoplastic thyroid tissue.

Fernández PL, Merino MJ, Gómez M, Campo E, Medina T, Castronovo V, Sanjuán X, Cardesa A, Liu FT, Sobel ME.

J Pathol. 1997 Jan;181(1):80-6.

PMID:
9072007
17.

Expression of galectin-3 in normal and malignant thyroid tissue by quantitative PCR and immunohistochemistry.

Feilchenfeldt J, Tötsch M, Sheu SY, Robert J, Spiliopoulos A, Frilling A, Schmid KW, Meier CA.

Mod Pathol. 2003 Nov;16(11):1117-23.

18.

Differential expression of galectin-3 in papillary projections of malignant and non-malignant hyperplastic thyroid lesions.

Cvejić D, Savin S, Petrović I, Paunović I, Tatić S, Havelka M.

Acta Chir Iugosl. 2003;50(3):67-70.

PMID:
15179758
19.

Proteomic identification of new biomarkers and application in thyroid cytology.

Torres-Cabala C, Bibbo M, Panizo-Santos A, Barazi H, Krutzsch H, Roberts DD, Merino MJ.

Acta Cytol. 2006 Sep-Oct;50(5):518-28.

PMID:
17017437
20.

Cyclin D1 in well differentiated thyroid tumour of uncertain malignant potential.

Lamba Saini M, Weynand B, Rahier J, Mourad M, Hamoir M, Marbaix E.

Diagn Pathol. 2015 Apr 18;10:32. doi: 10.1186/s13000-015-0262-8.

Supplemental Content

Support Center